Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Med Genomics ; 3: 40, 2010 Sep 13.
Article in English | MEDLINE | ID: mdl-20836844

ABSTRACT

BACKGROUND: Pathological angiogenesis represents a critical issue in the progression of many diseases. Down syndrome is postulated to be a systemic anti-angiogenesis disease model, possibly due to increased expression of anti-angiogenic regulators on chromosome 21. The aim of our study was to elucidate some features of circulating endothelial progenitor cells in the context of this syndrome. METHODS: Circulating endothelial progenitors of Down syndrome affected individuals were isolated, in vitro cultured and analyzed by confocal and transmission electron microscopy. ELISA was performed to measure SDF-1α plasma levels in Down syndrome and euploid individuals. Moreover, qRT-PCR was used to quantify expression levels of CXCL12 gene and of its receptor in progenitor cells. The functional impairment of Down progenitors was evaluated through their susceptibility to hydroperoxide-induced oxidative stress with BODIPY assay and the major vulnerability to the infection with human pathogens. The differential expression of crucial genes in Down progenitor cells was evaluated by microarray analysis. RESULTS: We detected a marked decrease of progenitors' number in young Down individuals compared to euploid, cell size increase and some major detrimental morphological changes. Moreover, Down syndrome patients also exhibited decreased SDF-1α plasma levels and their progenitors had a reduced expression of SDF-1α encoding gene and of its membrane receptor. We further demonstrated that their progenitor cells are more susceptible to hydroperoxide-induced oxidative stress and infection with Bartonella henselae. Further, we observed that most of the differentially expressed genes belong to angiogenesis, immune response and inflammation pathways, and that infected progenitors with trisomy 21 have a more pronounced perturbation of immune response genes than infected euploid cells. CONCLUSIONS: Our data provide evidences for a reduced number and altered morphology of endothelial progenitor cells in Down syndrome, also showing the higher susceptibility to oxidative stress and to pathogen infection compared to euploid cells, thereby confirming the angiogenesis and immune response deficit observed in Down syndrome individuals.


Subject(s)
Down Syndrome/pathology , Endothelium, Vascular/cytology , Stem Cells/pathology , Cat-Scratch Disease/genetics , Chemokine CXCL12/blood , Chemokine CXCL12/genetics , Chromosomes, Human, Pair 21 , Down Syndrome/genetics , Down Syndrome/metabolism , Humans , Hydrogen Peroxide/metabolism , Oxidative Stress , Phenotype , Stem Cells/metabolism , Trisomy
2.
J Biochem Mol Toxicol ; 24(6): 351-60, 2010.
Article in English | MEDLINE | ID: mdl-20665603

ABSTRACT

Exposure of human endothelial progenitor cells (EPCs) to tumor necrosis factor-α (TNF-α) reduced their number and biological activity. Yet, signal transduction events linked to TNF-α action are still poorly understood. To address this issue, we examined the possible effect of fasudil and Y27632, two inhibitors of Rho kinase pathway, which is involved in endothelial dysfunction, atherosclerosis, and in- flammation. Results demonstrated that incubation with fasudil starting from 50 µM but not Y27632 determined a dose-dependent improvement of EPC number during exposure to TNF-α (P < 0.05 vs. TNF-α alone). Analysis of the signal transduction pathway activated by TNF-α revealed that the increased expression of p-p38 was not significantly altered by fasudil. Instead, fasudil blocked the TNF-α induced phosphorylation of Erk1/2 (P < 0.05 vs. TNF-α) as well as the inhibitor of Erk1/2-specific phosphorylated form, i.e., PD98059 (P < 0.05 vs. TNF-α). These results were confirmed by analysis of these kinases by confocal microscopy. Finally, 2D-DIGE and MALDI-TOF/TOF analysis of EPCs treated with fasudil revealed increased expression levels of an actin-related protein and an adenylyl cyclase associated protein and decreased expression levels of proteins related to radical scavenger and nucleotide metabolism. These findings suggest that fasudil positively affects EPC number and that other major signals might take part to this complex pathway.


Subject(s)
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives , Amides/pharmacology , Endothelial Cells/pathology , Pyridines/pharmacology , Stem Cells/pathology , Tumor Necrosis Factor-alpha/pharmacology , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Cells, Cultured , Humans , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Signal Transduction , Two-Dimensional Difference Gel Electrophoresis
3.
Biochim Biophys Acta ; 1801(10): 1123-32, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20637897

ABSTRACT

Endothelial progenitor cell (EPC) therapy is a promising approach to promote angiogenesis and endothelial repair in patients with cardiovascular diseases (CVD). However, their release of proinflammatory mediators may compromise the therapeutic efficacy. Little is known about the role of Platelet-Activating Factor (PAF) in EPC functional response. Here, we investigated the expression of PAF receptor (PAF-R) in early EPC and the release of PAF under stimulation with factors involved in endothelial dysfunction. Results indicated that early EPC express the PAF-R and respond to PAF signaling via a transient increase of cytoplasmic Ca(2+) concentration. EPC release PAF in a time dependent manner upon stimulation with tumor necrosis factor-alpha (TNF-alpha) or high-glucose concentration with a peak at 30 min and 10 min (p<0.01 vs. control), respectively. PAF, starting at concentration of 50 ng/ml, exerted a detrimental effect on EPC number with a concomitant increase of p38 activity. Furthermore, both the reduction of early EPC number and the enhanced p38 activity induced by PAF were abolished by CV3988, a PAF receptor antagonist. These novel findings, revealing that early EPC respond to PAF signaling, unveil an inflammatory pathway that may play a crucial role in the outcome of cardiovascular cell therapy with EPC.


Subject(s)
Calcium Signaling/drug effects , Endothelial Cells/cytology , Endothelial Cells/metabolism , Platelet Activating Factor/pharmacology , Platelet Membrane Glycoproteins/metabolism , Receptors, G-Protein-Coupled/metabolism , Stem Cells/drug effects , Stem Cells/metabolism , Calcium/metabolism , Cell Count , Cell Survival/drug effects , Cytoplasm/drug effects , Cytoplasm/metabolism , Endothelial Cells/drug effects , Endothelial Cells/enzymology , Enzyme Activation/drug effects , Gene Expression Profiling , Gene Expression Regulation/drug effects , Glucose/pharmacology , Humans , Intracellular Space/drug effects , Intracellular Space/metabolism , MAP Kinase Signaling System/drug effects , Platelet Activating Factor/metabolism , Platelet Membrane Glycoproteins/genetics , Receptors, G-Protein-Coupled/genetics , Stem Cells/cytology , Stem Cells/enzymology , Tumor Necrosis Factor-alpha/pharmacology , p38 Mitogen-Activated Protein Kinases/metabolism
4.
Biochim Biophys Acta ; 1784(6): 936-45, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18423418

ABSTRACT

Increasing evidence indicates that mammalian SIRT1 mediates calorie restriction and influences lifespan regulating a number of biological molecules such as FoxO1. SIRT1 controls the angiogenic activity of endothelial cells via deacetylation of FoxO1. Endothelial dysfunction and reduced new blood vessel growth in diabetes involve a decreased bioactivity of endothelial progenitor cells (EPCs) via repression of FoxO1 transcriptional activity. The relative contribution of SIRT1 with respect to the direct effects of high glucose on EPC number is poorly understood. We report that treatment of EPCs with high glucose for 3 days determined a consistent downregulation of EPC positive to DiLDL/lectin staining and, interestingly, this was associated with reduced SIRT1 expression levels and enzyme activity, and increased acetyl-FoxO1 expression levels. Moreover, EPCs responded to high glucose with major changes in the expression levels of cell metabolism-, cell cycle-, and oxidative stress-related genes or proteins. Proteomic analysis shows increased expression of nicotinamide phosphoribosyl transferase and mitochondrial superoxide dismutase whereas a glucose-related heat shock protein is reduced. These findings show that SIRT1 is a critical modulator of EPCs dysfunction during alteration of glucose metabolism.


Subject(s)
Endothelial Cells/drug effects , Glucose/pharmacology , Sirtuins/metabolism , Stem Cells/drug effects , Acetylation/drug effects , Blotting, Western , Cell Count , Cells, Cultured , Endothelial Cells/cytology , Endothelial Cells/metabolism , Flow Cytometry , Forkhead Box Protein O1 , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , Gene Expression/drug effects , HeLa Cells , Humans , Oligonucleotide Array Sequence Analysis , Reverse Transcriptase Polymerase Chain Reaction , Sirtuin 1 , Sirtuins/genetics , Stem Cells/cytology , Stem Cells/metabolism
5.
Int J Cardiol ; 126(2): 295-7, 2008 May 23.
Article in English | MEDLINE | ID: mdl-18255172

ABSTRACT

Circulating endothelial progenitor cells (EPCs) play a significant role in regeneration of damaged blood vessels. Levels and functional activities of EPCs are noticeable altered by risk factors for coronary heart disease (CHD) and compounds that can prevent or ameliorate EPC dysfunction are currently of special clinical interest. Here, we evaluate the effects of red wine (RW) on EPCs in C57BL/6J mice subjected to physical exercise. FACS computed counting showed a significant increase of EPC number (P<0.05) in mice after short-term supplementation with RW. VEGF serum concentration was significantly increased by physical training in the presence or absence of RW supplementation (P<0.001). These in vivo observations support previous in vitro observation of the beneficial effect of RW in the modulation of EPC levels.


Subject(s)
Antioxidants/administration & dosage , Endothelial Cells/drug effects , Flavonoids/administration & dosage , Phenols/administration & dosage , Physical Conditioning, Animal/methods , Stem Cells/drug effects , Wine , Animals , Cell Proliferation/drug effects , Endothelial Cells/cytology , Endothelial Cells/physiology , Mice , Mice, Inbred C57BL , Polyphenols , Stem Cells/cytology , Stem Cells/physiology
6.
J Biochem ; 143(2): 179-86, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17984121

ABSTRACT

Circulating endothelial progenitor cells (EPCs) play a significant role in neovascularization of ischaemic tissues and in re-endothelization of injured blood vessels. Identification of compounds able to enhance EPC levels and improve their functional activity, noticeably compromised by risk factors for coronary heart disease, is of clinical interest. This study evaluates the effects of red wine on EPCs. After being isolated from total peripheral blood mononuclear cells, EPC phenotype was confirmed by the presence of double positive cells for DiLDL uptake and lectin binding and by expression of CD34, CD133 and VE-cadherin cell surface markers. Long-term culture in the presence of red wine (1 microl/ml), containing resveratrol (Resv) at physiological concentration (nM), determined a time-dependent amelioration of cell number (P < 0.05). The presence of red wine prevented the TNF-alpha-induced reduction of EPC number (P < 0.05) and this effect was accompanied by reduced p38-phosphorylation expression levels (P < 0.05) and increased NOx levels (P < 0.05) Indeed, pure Resv alone significantly improved the TNF-alpha reduced EPC number (P < 0.05). This evidence indicates novel beneficial effects of red wine and Resv in the positive modulation of EPCs levels.


Subject(s)
Endothelium, Vascular/drug effects , Stem Cells/drug effects , Stilbenes/pharmacology , Wine , Blotting, Western , Dose-Response Relationship, Drug , Endothelium, Vascular/cytology , Humans , Phosphorylation , Resveratrol , Stilbenes/administration & dosage , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL